Julian Baker’s Kymera Therapeutics KYMR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$993M Hold
8,657,242
4.97% 6
2026
Q1
$721M Hold
8,657,242
4.14% 9
2025
Q4
$674M Buy
8,657,242
+2,005,813
+30% +$135M 3.94% 8
2025
Q3
$376M Hold
6,651,429
2.72% 10
2025
Q2
$290M Buy
6,651,429
+655,500
+11% +$22.6M 2.82% 9
2025
Q1
$164M Hold
5,995,929
1.82% 9
2024
Q4
$241M Hold
5,995,929
2.58% 9
2024
Q3
$284M Buy
5,995,929
+1
+0% +$44 2.94% 9
2024
Q2
$179M Hold
5,995,928
2.29% 10
2024
Q1
$241M Hold
5,995,928
3.02% 7
2023
Q4
$153M Buy
5,995,928
+1,245,528
+26% +$22.3M 1.74% 8
2023
Q3
$66M Buy
4,750,400
+375,060
+9% +$7.54M 0.38% 19
2023
Q2
$101M Buy
4,375,340
+1,495,515
+52% +$42.9M 0.58% 15
2023
Q1
$85.3M Hold
2,879,825
0.46% 13
2022
Q4
$71.9M Hold
2,879,825
0.43% 17
2022
Q3
$62.7M Hold
2,879,825
0.41% 23
2022
Q2
$56.7M Buy
2,879,825
+495,083
+21% +$11.6M 0.32% 21
2022
Q1
$101M Hold
2,384,742
0.58% 14
2021
Q4
$151M Hold
2,384,742
0.74% 11
2021
Q3
$140M Buy
2,384,742
+425,531
+22% +$24.7M 0.62% 15
2021
Q2
$95M Hold
1,959,211
0.42% 22
2021
Q1
$76.1M Hold
1,959,211
0.33% 28
2020
Q4
$121M Hold
1,959,211
0.46% 18
2020
Q3
$63.3M Buy
+1,959,211
New +$59.8M 0.25% 25

Other funds holding KYMR

Julian Baker's KYMR Position: Q2 2026 in Review

Julian Baker held its Kymera Therapeutics (KYMR) position steady in Q2 2026 at 8,657,242 shares worth $993M. The position accounts for 4.97% of the portfolio, ranked #6.

Julian Baker first reported a position in KYMR in Q3 2020 and has held it in 24 quarters since. 273 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Julian Baker held 8,657,242 shares of Kymera Therapeutics worth $993M as of Q2 2026.
  • Julian Baker left its Kymera Therapeutics share count unchanged in Q2 2026.
  • Kymera Therapeutics made up 4.97% of Julian Baker's portfolio in Q2 2026, its #6 holding.
  • Julian Baker first reported a position in Kymera Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • 273 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Baker Bros. Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.